The Journal of the American Medical...
The Journal of the American Medical Association published clinical outcomes evaluating Replagal (agalsidase alfa, Transkaryotic Therapies, Inc., Cambridge, MA) enzyme replacement therapy as a treatment for Fabry's disease. The 26-subject double-blind, placebo-controlled Phase 2 consideration was conducted to assess multiple clinical result measures. The National Institutes of Health investigators reported that treated bring under rules had a clinically significant reduction in pain; those in the placebo clump showed no change. Subjects also experienced a reduction in the number of days against pain ...
Free Guitar Tabs |